FDA Approves Satsuma Pharma's Atzumi Nasal Powder For Acute Treatment Of Migraine
1/5 02:42
(RTTNews) - Satsuma Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved a 505(b)(2) New Drug Application (NDA) for Atzumi(dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previo...